Scarica l'app Stockscreener
4.89
1.41%
-0.06
Dopo l'orario di chiusura:
5.00
0.11
+2.25%
Precedente Chiudi:
$4.95
Aprire:
$4.95
Volume 24 ore:
20,478
Relative Volume:
0.41
Capitalizzazione di mercato:
$6.09M
Reddito:
$12.99M
Utile/perdita netta:
$-27.45M
Rapporto P/E:
-0.00275
EPS:
-1779.0561
Flusso di cassa netto:
$-25.59M
1 W Prestazione:
+9.66%
1M Prestazione:
+0.21%
6M Prestazione:
-78.82%
1 anno Prestazione:
-95.08%
Intervallo 1D:
$4.71
$4.98
Intervallo di 1 settimana:
$4.41
$5.22
Portata 52W:
$3.80
$235.98
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Nome
Aptevo Therapeutics Inc
Settore
Industria
Telefono
206-838-0500
Indirizzo
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.89 | 6.17M | 12.99M | -27.45M | -25.59M | -1,779.06 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-11-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-10-05 | Ripresa | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Borsa (APVO) Ultime notizie
APVO News | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
Aptevo (APVO) Q1 2026 Earnings: Soft Quarter Raises QuestionsEarnings Miss Alert - Newser
All you need to know about Aptevo Therapeutics (APVO) rating upgrade to buy - MSN
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy - Yahoo Finance
Aptevo (APVO) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Consistency Score - Newser
Key facts: Aptevo Q1 loss $0.01/sh; mipletamig shows 87% clinical benefit - TradingView
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo reports clinical trial results for AML drug candidate By Investing.com - Investing.com India
Aptevo (APVO) Positioned for Growth with Promising Pipeline and Leadership - GuruFocus
Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptevo Therapeutics (NASDAQ: APVO) warns on going concern after $6.7M Q1 loss - Stock Titan
Strong AML data and $60M equity facility in Aptevo (NASDAQ: APVO) Q1 update - Stock Titan
Aptevo Therapeutics Updates on Q1 2026 Progress and Leadership T - GuruFocus
Aptevo reports clinical trial results for AML drug candidate - Investing.com UK
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - ACCESS Newswire
Leukemia trial hits 81% remission; Aptevo lines up $60M equity line - Stock Titan
APVO Price Today: Aptevo Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
TradingKey - TradingKey
Number of shareholders of Aptevo Therapeutics, Inc. – GETTEX:AP82 - TradingView
10-K - SEC.gov
Aptevo Therapeutics Inc expected to post a loss of $5.60 a shareEarnings Preview - TradingView
Aptevo Therapeutics (APVO) Reports Encouraging Results in AML Tr - GuruFocus
Aptevo Highlights Strong Phase 1b AML Trial Results - TipRanks
Aptevo (Nasdaq: APVO) reports 81% AML remission in RAINIER study - Stock Titan
Aptevo reports 87% clinical benefit rate in AML trial By Investing.com - Investing.com Australia
Aptevo reports 87% clinical benefit rate in AML trial - Investing.com UK
6 AML patients reached transplant as Aptevo enters final dose stage - Stock Titan
Aptevo Reports 87% Clinical Benefit And 81% Remission In Frontline AML Trial; Stock Down - RTTNews
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - ACCESS Newswire
APVO Q1'26 Earnings: EPS estimate is (5.60) USD - TradingView
APVO Forecast, Price Target & Analyst Ratings | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
Aptevo Therapeutics shares jump after $60 million equity facility secured - MSN
Aptevo Therapeutics (APVO) upgraded to buy: Here's why - MSN
APVO Price History for Aptevo Therapeutics Stock - Barchart.com
APVO Aptevo Therapeutics Inc. reports vastly stronger Q4 2025 EPS than expected, shares climb 7.16 percent today.Social Trade Signals - Xã Thanh Hà
Aptevo Therapeutics posts 99.9% EPS surprise far narrower loss than expectedCommunity Momentum Stocks - Xã Thanh Hà
Aptevo (APVO) Stock Technical Trade (Investors Pile In) 2026-04-22Shared Momentum Picks - Cổng thông tin điện tử Tỉnh Sơn La
Aptevo (APVO) Stock: Fast Summary (Weakens) 2026-04-20Fast Moving Stocks - UBND thành phố Hải Phòng
Risk On: Is Aptevo Therapeutics Inc impacted by rising ratesPortfolio Update Report & AI Driven Price Forecasts - baoquankhu1.vn
Aug Chart Watch: What is Aptevo Therapeutics Incs valuation compared to sector2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
Can Aptevo (APVO) Stock Beat the Market | Price at $4.45, Up 1.60%Insider Info - Cổng thông tin điện tử tỉnh Lào Cai
Aptevo Therapeutics Inc Azioni (APVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.49%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):